Treatment of therapy-resistant acute myeloid leukaemia with 7 and 8 cytostatics.
16 courses of an 8-drug regimen including daunomycin, vincristine, cytosinearabinoside, thioguanine, methotrexate, cyclophosphamide, prednisolone and hydroxyurea, and 12 courses of a 7-drug regimen including the same drugs minus hydroxyurea were administered in 16 otherwise therapy-resistant cases of acute myeloid leukaemia. In spite of a significant and rapid reduction of the leukaemic cell-mass in all the cases treated, only two brief minimal remissions were obtained. The main toxic effect was myelosuppression. However, the treatment was associated with a high frequency of mucosal ulcerations of the oesophagus and stomach, and it cannot be excluded that the latter complication may be drug-related.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002177:Candidiasis; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004942:Esophagitis, Peptic / Q000139:chemically induced; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000139:chemically induced; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D013866:Thioguanine; D006918:Hydroxyurea; D008727:Methotrexate; D003630:Daunorubicin